{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:50:26Z","timestamp":1791517826279,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.jaad.2014.04.040","type":"journal-article","created":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T01:31:49Z","timestamp":1401845509000},"page":"475-479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Two decades of using the combination of tetracycline derivatives and niacinamide as steroid-sparing agents in the management of pemphigus: Defining a niche for\u00a0these low toxicity agents"],"prefix":"10.1016","volume":"71","author":[{"given":"Morgan","family":"McCarty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fivenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2014.04.040_bib1","first-page":"844","article-title":"Autoimmune bullous skin diseases. Part 1: clinical manifestations","volume":"9","author":"Kneisel","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2014.04.040_bib2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.clindermatol.2011.01.013","article-title":"Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis)","volume":"29","author":"Joly","year":"2011","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2014.04.040_bib3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.det.2011.07.001","article-title":"Evidence-based treatments in pemphigus vulgaris and pemphigus foliaceus","volume":"29","author":"Frew","year":"2011","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2014.04.040_bib4","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jaad.2010.04.039","article-title":"A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus","volume":"64","author":"Martin","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.04.040_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/archderm.144.1.25","article-title":"Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris","volume":"144","author":"Werth","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.04.040_bib6","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archderm.1994.01690060083010","article-title":"Niacinamide and tetracycline therapy of bullous pemphigoid","volume":"130","author":"Fivenson","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.04.040_bib7","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2165\/00002512-200522070-00003","article-title":"The role of topical corticosteroids in bullous pemphigoid in the elderly","volume":"22","author":"Joly","year":"2005","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jaad.2014.04.040_bib8","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0190-9622(08)80651-2","article-title":"Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases","volume":"28","author":"Chaffins","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.04.040_bib9","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1346-8138.2010.00920.x","article-title":"Tetracycline and niacinamide control bullous pemphigoid but not pemphigus foliaceus when these conditions coexist","volume":"37","author":"Shiohara","year":"2010","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2014.04.040_bib10","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/archderm.1986.01660180076019","article-title":"The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report","volume":"122","author":"Berk","year":"1986","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.04.040_bib11","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/archderm.1995.01690230121025","article-title":"Is the combination of tetracycline and nicotinamide alone effective in pemphigus?","volume":"131","author":"Alpsoy","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.04.040_bib12","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.04.040_bib13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jaad.2004.02.013","article-title":"Management of autoimmune bullous diseases: pharmacology and therapeutics","volume":"51","author":"Mutasim","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.04.040_bib14","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2005.10.004","article-title":"Tetracyclines: nonantibiotic properties and their clinical implications","volume":"54","author":"Sapadin","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.04.040_bib15","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/humu.20981","article-title":"Cytokines as genetic modifiers in K5-\/- mice and in human epidermolysis bullosa simplex","volume":"30","author":"Roth","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jaad.2014.04.040_bib16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1600-0625.2012.01534.x","article-title":"Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promise","volume":"21","author":"Chamcheu","year":"2012","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2014.04.040_bib17","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1038\/sj.jid.5700918","article-title":"Induction of inflammatory cytokines by a keratin mutation and their repression by a small molecule in a mouse model for EBS","volume":"127","author":"Lu","year":"2007","journal-title":"J Invest Dermatol"},{"issue":"1 suppl","key":"10.1016\/j.jaad.2014.04.040_bib18","first-page":"5","article-title":"The mechanisms of action of nicotinamide and\u00a0zinc in inflammatory skin disease","volume":"77","author":"Fivenson","year":"2006","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2014.04.040_bib19","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jnutbio.2010.10.009","article-title":"The anti-inflammatory and antioxidative effects of nicotinamide, a vitamin B(3) derivative, are elicited by FoxO3 in human gestational tissues: implications for preterm birth","volume":"22","author":"Lappas","year":"2011","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.jaad.2014.04.040_bib20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jdermsci.2013.02.011","article-title":"A higher correlation of the antibody activities against the calcium-dependent epitopes of desmoglein 3 quantified by ethylenediaminetetraacetic acid-treated enzyme-linked immunosorbent assay with clinical disease activities of pemphigus vulgaris","volume":"70","author":"Kamiya","year":"2013","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2014.04.040_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1726-4901(09)70304-1","article-title":"Using desmoglein 1 and 3 enzyme-linked immunosorbent assay as an adjunct diagnostic tool for pemphigus","volume":"70","author":"Huang","year":"2007","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.jaad.2014.04.040_bib22","first-page":"48","article-title":"Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins","volume":"84","author":"Herzog","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2014.04.040_bib23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archdermatol.2009.9","article-title":"ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus","volume":"145","author":"Abasq","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.04.040_bib24","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/j.1468-3083.2008.02715.x","article-title":"Anti-desmoglein IgG autoantibodies in patients with pemphigus in remission","volume":"22","author":"Kwon","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2014.04.040_bib25","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2011.12.019","article-title":"Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up","volume":"67","author":"Reguiai","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.04.040_bib26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archderm.1996.03890260105016","article-title":"The adjuvant therapy of pemphigus. An update","volume":"132","author":"Bystryn","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.04.040_bib27","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/archderm.135.10.1275","article-title":"Methotrexate as an adjuvant treatment for pemphigus vulgaris","volume":"135","author":"Smith","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.04.040_bib28","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archderm.134.9.1104","article-title":"Treatment of pemphigus with gold","volume":"134","author":"Pandya","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.04.040_bib29","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1067\/mjd.2001.116339","article-title":"Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional treatment","volume":"45","author":"Ahmed","year":"2001","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214013930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214013930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:30:43Z","timestamp":1759271443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962214013930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0190962214013930"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2014.04.040","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two decades of using the combination of tetracycline derivatives and niacinamide as steroid-sparing agents in the management of pemphigus: Defining a niche for\u00a0these low toxicity agents","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2014.04.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}